BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 21824109)

  • 1. Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy.
    Frezza M; Schmitt S; Dou QP
    Curr Top Med Chem; 2011 Dec; 11(23):2888-905. PubMed ID: 21824109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.
    Yang H; Landis-Piwowar KR; Chen D; Milacic V; Dou QP
    Curr Protein Pept Sci; 2008 Jun; 9(3):227-39. PubMed ID: 18537678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.
    Dalla Via L; Nardon C; Fregona D
    Future Med Chem; 2012 Mar; 4(4):525-43. PubMed ID: 22416778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy.
    Driscoll JJ; Dechowdhury R
    Target Oncol; 2010 Dec; 5(4):281-9. PubMed ID: 21125340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.
    Soave CL; Guerin T; Liu J; Dou QP
    Cancer Metastasis Rev; 2017 Dec; 36(4):717-736. PubMed ID: 29047025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the proteasome pathway.
    Tsukamoto S; Yokosawa H
    Expert Opin Ther Targets; 2009 May; 13(5):605-21. PubMed ID: 19397479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the ubiquitin+proteasome system in solid tumors.
    Driscoll JJ; Woodle ES
    Semin Hematol; 2012 Jul; 49(3):277-83. PubMed ID: 22726552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proteasome: a novel target for anticancer therapy.
    Montagut C; Rovira A; Albanell J
    Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention.
    Chen D; Dou QP
    Curr Protein Pept Sci; 2010 Sep; 11(6):459-70. PubMed ID: 20491623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
    Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP
    Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
    Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
    Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
    D'Arcy P; Brnjic S; Olofsson MH; Fryknäs M; Lindsten K; De Cesare M; Perego P; Sadeghi B; Hassan M; Larsson R; Linder S
    Nat Med; 2011 Nov; 17(12):1636-40. PubMed ID: 22057347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome: an emerging target for cancer therapy.
    Zavrski I; Jakob C; Schmid P; Krebbel H; Kaiser M; Fleissner C; Rosche M; Possinger K; Sezer O
    Anticancer Drugs; 2005 Jun; 16(5):475-81. PubMed ID: 15846112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting ubiquitin-proteasome pathway by natural, in particular polyphenols, anticancer agents: Lessons learned from clinical trials.
    Nabavi SF; Atanasov AG; Khan H; Barreca D; Trombetta D; Testai L; Sureda A; Tejada S; Vacca RA; Pittalà V; Gulei D; Berindan-Neagoe I; Shirooie S; Nabavi SM
    Cancer Lett; 2018 Oct; 434():101-113. PubMed ID: 30030139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Proteasome inhibitor].
    Yamamura M; Hirai T; Yamaguchi Y
    Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment.
    Yang H; Chen X; Li K; Cheaito H; Yang Q; Wu G; Liu J; Dou QP
    Semin Cancer Biol; 2021 Jan; 68():105-122. PubMed ID: 31883910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.
    Liu N; Liu C; Li X; Liao S; Song W; Yang C; Zhao C; Huang H; Guan L; Zhang P; Liu S; Hua X; Chen X; Zhou P; Lan X; Yi S; Wang S; Wang X; Dou QP; Liu J
    Sci Rep; 2014 Jun; 4():5240. PubMed ID: 24912524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibitors: a therapeutic strategy for haematological malignancy.
    Crawford LJ; Walker B; Irvine AE
    Front Biosci; 2008 May; 13():4285-96. PubMed ID: 18508511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem.
    Landis-Piwowar KR
    Clin Lab Sci; 2012; 25(1):38-44. PubMed ID: 22458048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.